Prof B spoke at the iWiMS for 8 min. Here it is:
And here is a summary of the Swedish data presented by Jan Hillert.
And the following are our crude statistical analyses of the Swedish data:
Despite no correction of confounders the difference between Rituximab and other DMTs in terms of getting COVID-19 is highly significant and therefore likely to be biologically significant (bad news for anti-CD20 therapies).
However, in Swedish patients with COVID-19 the severity of COVID-19, i.e. requiring hospitalisation or ITU, does not appear to be more common in patients treated with rituximab so far. Please be aware that these analyses are based on very low numbers and hence may change in time when more cases are reported.